文献速递肝病

系统综述与荟萃分析:非酒精性脂肪性肝病中肝纤维化与亚临床动脉粥样硬化的关联

Systematic review and meta-analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2023-06-22

该系统综述与荟萃分析检索四个数据库至2023年2月,纳入12项研究共4725例非酒精性脂肪性肝病患者,评估肝纤维化与亚临床动脉粥样硬化的关联。汇总OR为2.18(95%CI:1.62-2.93),且纤维化程度越重关联越强,≥F1、≥F2、≥F3的OR分别为1.64、2.22、3.42。

要点

  • 非酒精性脂肪性肝病患者中,任何程度肝纤维化与亚临床动脉粥样硬化显著相关,汇总OR 2.18(95%CI:1.62-2.93)。
  • 纤维化程度越重关联越强:≥F1 OR 1.64、≥F2 OR 2.22、≥F3 OR 3.42。
  • 西方与东方人群及不同亚临床动脉粥样硬化测量方法间无显著差异。

核心结论

  • 任何程度的肝纤维化均与亚临床动脉粥样硬化显著相关,且纤维化严重程度可放大该关联。

研究设计与样本

  • 系统综述与荟萃分析,检索四个数据库1950年至2023年2月,纳入12项研究共4725例非酒精性脂肪性肝病患者,采用PICOS框架,两名评价者独立筛选,Newcastle-Ottawa量表评估质量,DerSimonian-Liard随机效应模型进行荟萃分析。

主要发现

  • 亚临床动脉粥样硬化的汇总OR为2.18(95%CI:1.62-2.93),提示与非酒精性脂肪性肝病中的肝纤维化显著相关。
  • 亚组分析显示纤维化越重OR越高:≥F1为1.64(95%CI:1.22-2.20),≥F2为2.22(95%CI:1.37-3.62),≥F3为3.42(95%CI:1.81-6.46)。
  • 西方与东方人群之间以及不同亚临床动脉粥样硬化测量方法之间无显著差异。

关键数值与推荐

  • 亚临床动脉粥样硬化汇总OR 2.18(95%CI:1.62-2.93)。
  • ≥F1纤维化OR 1.64(95%CI:1.22-2.20)。
  • ≥F2纤维化OR 2.22(95%CI:1.37-3.62)。
  • ≥F3纤维化OR 3.42(95%CI:1.81-6.46)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a liver disorder commonly associated with metabolic syndrome and cardiovascular disease (CVD). Atherosclerosis, a leading cause of CVD, has been linked to liver fibrosis. However, the evidence regarding this association is conflicting. AIM: To evaluate the link between liver fibrosis and subclinical atherosclerosis in patients with NAFLD METHODS: We conducted a comprehensive search of four databases from 1950 to February 2023 to identify eligible studies investigating the association between liver fibrosis and subclinical atherosclerosis among patients with NAFLD, utilising the PICOS framework. Two independent reviewers screened the studies; quality was assessed using the Newcastle-Ottawa Scale. Meta-analysis was performed using the DerSimonian-Liard random-effects model, and subgroup analysis was conducted based on the severity of liver fibrosis, type of subclinical atherosclerosis diagnosis and geographic region. RESULTS: The meta-analysis included 12 studies with a total of 4725 patients. Overall pooled odds ratio (OR) for subclinical atherosclerosis was 2.18 (95% CI: 1.62-2.93), indicating a significant association with liver fibrosis in NAFLD. Subgroup analysis revealed higher ORs in patients with more severe fibrosis: 1.64 (95% CI: 1.22-2.20) in ≥F1, 2.22 (95% CI: 1.37-3.62) in ≥F2, and 3.42 (95% CI: 1.81-6.46) in ≥F3. However, there was no significant difference between the West versus East and various measurements of subclinical atherosclerosis. CONCLUSIONS: Any degree of fibrosis is significantly associated with subclinical atherosclerosis, with fibrosis severity amplifying the association.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jamalinia M, Zare F, Lankarani KB, et al. Systematic review and meta-analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2023. PMID: 37345533. doi:10.1111/apt.17617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。